肿瘤标志物联合检测肺癌的临床价值

目的：评价肿瘤标志物多项联合检测肺癌的临床意义。方法：采用放射免疫法检测91例肺癌、58例肺良性疾病（如肺炎等）患者和48例正常健康人群血清中CEA，NSE，CYFRA21—1，CA125的水平。结果：肺癌组CEA，NSE，CYFRA21—1，CA125肿瘤标志物水平及阳性率均高于肺良性疾病组和正常对照组，差异有统计学意义（P〈0．01）。4项肿瘤标记物测定水平和灵敏度与病理类型有关，其中血CEA以腺癌最高，血NSE以小细胞肺癌最高，血CYFRA21—1以鳞癌最高，CAl25以非小细胞肺癌最高。联合检测血清CEA，NSE，CA125及CYFRA21—1水平，对诊断肺癌的敏感性为90．8％，特异度为86．5％。结论：肿瘤标志物的联合检测可提高肿瘤诊断的敏感性和特异性。

Clinical Value of Combined Detection of Tumor Markers for Lung Cancer

Objective： To evaluate the clinical significance of multiple combined detection of tumor markers for lung cancer. Methods ：The levels of CEA, NSE, CYFRA21-1 and CA125 in serum of 91 patients with lung cancer,58 patients with benign lung diseases and 48 normal healthy people were measured by radioimmunoassay. Results：The serum levels of markers CEA, NSE, CYFRA21-1 and CA125 and the positive rate in the lung cancer group were higher than those in the benign lung diseases group and the normal control group. There was statistical difference （P 〈 0.01 ）. The detective levels and the sensitivity of the four tumor markers CEA, NSE, CYFRA21-1 and CA125 were related to the pathology type. The serum CEA was highest in adenocarcinoma, the serum NSE was highest in small-cell lung cancer, the serum CYFRA21-1 was highest in squamous cell cancer and the serum CA125 was highest in non-small-cell lung cancer respectively. The sensitivity was 90.8% and the specificity was 86.5% by the combined detection serum CEA, NSE, CYFRA21-1 and CA125 for diagnosis of lung cancer. Conclusion： The combined detection of the tumor markers may improve the sensitivity and specificity for diagnosis of lung cancer.